Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...
Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports ...
In a world increasingly attuned to environmental responsibility, Sutro Biopharma remains committed to sustainability. Our journey towards greener practices is evident through our Green Business ...
Sutro Biopharma, Inc. (NASDAQ:STRO) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for STRO is 71.8.
Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat reports. One ...
Sutro Biopharma (STRO) delivered earnings and revenue surprises of 20.27% and 53.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients ...
SUTRO BIOPHARMA, INC. 競合他社・同業他社分析 - Life Sciences セクター
Our AI model demonstrates 59% historical accuracy for STRO predictions, based on advanced machine learning algorithms trained on over 10 years of market data.